COVID-19 will impact both the program content and attendees this year, but there are still important HIV science presentations.
While it is too soon to tell, this research involving broadly neutralizing antibodies could point to new methods for preventing vertical transmission.
Dec. 12, 2019: A lot of catchup to do before “Ending the HIV Epidemic”; the value of online HIV self-test distribution; viral suppression is about more than basic HIV treatment services; effect of hormone therapy on PrEP levels.
Oct. 24, 2019: A computerized antiretroviral recommendation tool; higher Fiebig stage equals more frequent viral load blips; low prescription refill rates among Americans starting treatment; internalized stigma and HIV outcomes.
This population is under-represented in HIV data, and few prevention or treatment interventions exist to support them. A new meta-analysis hopes to paint a picture of what's needed.
But other research links prisons themselves to mental health challenges and infectious disease outbreaks.
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
A chlamydia infection makes HIV acquisition more likely.
Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
Will potential study participants choose a vaccine trial over getting access to PrEP?